Identification of stool miR-135b-5p as a non-invasive diaognostic biomarker in later tumor stage of colorectal cancer.
Author(s): Li L, Wang A, Cai M, Tong M, Chen F, Huang L
Publication: Life Sci, 2020, Vol. 260, Page 118417
PubMed ID: 32931801 PubMed Review Paper? No
Purpose of Paper
This paper compared microRNA (miRNA, miR)-135b-5p levels in serum and fecal specimens from colorectal cancer (CRC) patients and healthy volunteers. Differences in miR-135b-5p levels based on tumor stage were also investigated.
Conclusion of Paper
Levels of miR-135b-5p were comparable in serum and fecal specimens from stage-I CRC patients and healthy patients, but significantly higher in specimens from stage-II, stage-III, and stage-IV CRC patients than healthy patients. Receiver operating and characteristic (ROC) curve analysis showed that miR-135b-5p levels in serum and feces effectively distinguished CRC patients from healthy patients and there was no significant difference between the area under curve (AUC) of serum and feces, indicating comparable diagnostic utility.
Studies
-
Study Purpose
This study compared miR-135b-5p expression levels in serum and fecal specimens from colorectal cancer patients and healthy volunteers. Differences in miR-135b-5p levels based on tumor stage were also investigated. Serum and fecal specimens were collected from 77 colorectal cancer patients (11 stage-I, 9 stage-II, 23 stage-III, and 34 stage-IV) and 29 healthy controls (no collection or processing details provided). RNA was extracted from fecal specimens using Stool Total RNA Purification Kit Dx and quantified by spectrophotometry. Details for serum processing were not provided. Levels of miR-135b-5p were measured by real-time qRT-PCR.
Summary of Findings:
Levels of miR-135b-5p were comparable in serum and fecal specimens from stage-I CRC patients and healthy volunteers, but were 3.12, 6.53, and 7.42-fold higher in serum specimens from stage-II, stage-III, and stage-IV CRC patients than healthy volunteers, respectively, and 4.39, 9.19, and 13.5-fold higher in fecal specimens, respectively (P<0.05, all). ROC curve analysis showed that miR-135b-5p levels in serum and feces effectively distinguished CRC patients from healthy volunteers with a specificity of 72.7% and 74.1%, respectively, and sensitivity of 93.1% and 96.5%; respectively. There was no significant difference between the area under curve (AUC) of serum and feces (0.83 and 0.87, P=0.2559), indicating comparable diagnostic utility.
Biospecimens
Preservative Types
- None (Fresh)
Diagnoses:
- Neoplastic - Carcinoma
Platform:
Analyte Technology Platform RNA Real-time qRT-PCR RNA Spectrophotometry Pre-analytical Factors:
Classification Pre-analytical Factor Value(s) Real-time qRT-PCR Specific Targeted nucleic acid miR-135b-5p
Biospecimen Acquisition Biospecimen location Feces
Serum